Stay updated on Pembrolizumab for High Risk Oral Neoplasia Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High Risk Oral Neoplasia Clinical Trial page.

Latest updates to the Pembrolizumab for High Risk Oral Neoplasia Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no substantive changes to the study details are visible.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page now lists Revision: v3.3.1; Revision: v3.2.0 was removed.SummaryDifference0.1%

- Check27 days agoChange DetectedThe government funding/operating status notice was removed from the page. This change does not affect the study details or data presented on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedThe study record now shows updated results posting dates and last update timestamps.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded Results Posted section with Overall Survival and Oral Cancer-free Survival, including time frames and Kaplan-Meier analysis, and a link to the Study Protocol and SAP PDF. Removed Exploratory Objectives on oral microbiome, neo-antigens, and immune infiltrates from the study plan.SummaryDifference2%

- Check70 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference4%

Stay in the know with updates to Pembrolizumab for High Risk Oral Neoplasia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High Risk Oral Neoplasia Clinical Trial page.